Media Reporting of Practice-Changing Clinical Trials in Oncology: A North American Perspective

被引:3
|
作者
Andrew, Peter [1 ]
Vickers, Michael M. [1 ]
O'Connor, Stephen [2 ]
Valdes, Mario [3 ]
Tang, Patricia A. [4 ]
机构
[1] Univ Ottawa, Div Med Oncol, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada
[2] City Univ London, London EC1V 0HB, England
[3] Grand River Reg Canc Ctr, Kitchener, ON, Canada
[4] Univ Calgary, Dept Med Oncol, Tom Baker Canc Ctr, Calgary, AB, Canada
来源
ONCOLOGIST | 2016年 / 21卷 / 03期
关键词
Clinical trials; Journalism; Neoplasms; Social media; TRASTUZUMAB PLUS DOCETAXEL; CANCER-PATIENTS; GOOGLE-SCHOLAR; NEWS MEDIA; DOUBLE-BLIND; INTERNET USE; TWITTER USE; PHASE-III; CHEMOTHERAPY; CITATIONS;
D O I
10.1634/theoncologist.2015-0056
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction. Media reporting of clinical trials impacts patient-oncologist interactions. We sought to characterize the accuracy of media and Internet reporting of practice-changing clinical trials in oncology. Materials and Methods. The first media articles referencing 17 practice-changing clinical trials were collected from 4 media outlets: newspapers, cable news, cancer websites, and industry websites. Measured outcomes were media reporting score, social media score, and academic citation score. The media reporting score was a measure of completeness of information detailed in media articles as scored by a 15-point scoring instrument. The social media score represented the ubiquity of social media presence referencing 17 practice-changing clinical trials in cancer as determined by the American Society of Clinical Oncology in its annual report, entitled Clinical Cancer Advances 2012; social media score was calculated from Twitter, Facebook, and Google searches. The academic citation score comprised total citations from Google Scholar plus the Scopus database, which represented the academic impact per clinical cancer advance. Results. From 170 media articles, 107 (63%) had sufficient data for analysis. Cohen's kappa coefficient demonstrated reliability of the media reporting score instrument with a coefficient of determination of 94%. Per the media reporting score, information was most complete from industry, followed by cancer websites, newspapers, and cable news. The most commonly omitted items, in descending order, were study limitations, exclusion criteria, conflict of interest, and other. The social media score was weakly correlated with academic citation score. Conclusion. Media outlets appear to have set a low bar for coverage of many practice-changing advances in oncology, with reports of scientific breakthroughs often omitting basic study facts and cautions, which may mislead the public. The media should be encouraged to use a standardized reporting template and provide accessible references to original source information whenever feasible.
引用
收藏
页码:269 / 278
页数:10
相关论文
共 50 条
  • [31] Reporting outcome comparisons by sex in oncology clinical trials
    Zhao, Guo
    Wang, Yuning
    Wang, Shuhang
    Li, Ning
    NATURE COMMUNICATIONS, 2024, 15 (01) : 3051
  • [32] GUIDELINES FOR ANALYSIS AND REPORTING OF CLINICAL-TRIALS IN ONCOLOGY
    PIANTADOSI, S
    SAIJO, N
    TAMURA, T
    JAPANESE JOURNAL OF CANCER RESEARCH, 1993, 84 (09): : 929 - 937
  • [33] Changing Climates, Changing Forests: A Western North American Perspective
    Fettig, Christopher J.
    Reid, Mary L.
    Bentz, Barbara J.
    Sevanto, Sanna
    Spittlehouse, David L.
    Wang, Tongli
    JOURNAL OF FORESTRY, 2013, 111 (03) : 214 - 228
  • [34] Participation of emerging regions in practice-changing breast cancer trials over the last three decades
    Machado, Andres
    Rodriguez, Clara
    Migliaro, Andrea
    Fresco, Rodrigo
    CANCER RESEARCH, 2020, 80 (04)
  • [35] Textbook of Clinical Trials in Oncology: A statistical Perspective
    Shanmugam, Ramalingam
    JOURNAL OF STATISTICAL COMPUTATION AND SIMULATION, 2021, 91 (09) : 1908 - 1909
  • [36] Textbook of clinical trials in oncology: a statistical perspective
    Jin, Man
    Fang, Yixin
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2020, 30 (02) : 402 - 403
  • [37] American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
    Ellis, Lee M.
    Bernstein, David S.
    Voest, Emile E.
    Berlin, Jordan D.
    Sargent, Daniel
    Cortazar, Patricia
    Garrett-Mayer, Elizabeth
    Herbst, Roy S.
    Lilenbaum, Rogerio C.
    Sima, Camelia
    Venook, Alan P.
    Gonen, Mithat
    Schilsky, Richard L.
    Meropol, Neal J.
    Schnipper, Lowell E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) : 1277 - +
  • [38] Changing trends in phase 1 oncology clinical trials
    Kelly, Richard
    Guo, Christina
    Desai, Jayesh
    Tran, Ben
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2024, 37
  • [39] Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial
    Abigail S. Caudle
    Kelly K. Hunt
    Henry M. Kuerer
    Funda Meric-Bernstam
    Anthony Lucci
    Isabelle Bedrosian
    Gildy V. Babiera
    Rosa F. Hwang
    Merrick I. Ross
    Barry W. Feig
    Karen Hoffman
    Jennifer K. Litton
    Aysegul A. Sahin
    Wei Yang
    Gabriel N. Hortobagyi
    Thomas A. Buchholz
    Elizabeth A. Mittendorf
    Annals of Surgical Oncology, 2011, 18 : 2407 - 2412
  • [40] Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial
    Caudle, Abigail S.
    Hunt, Kelly K.
    Kuerer, Henry M.
    Meric-Bernstam, Funda
    Lucci, Anthony
    Bedrosian, Isabelle
    Babiera, Gildy V.
    Hwang, Rosa F.
    Ross, Merrick I.
    Feig, Barry W.
    Hoffman, Karen
    Litton, Jennifer K.
    Sahin, Aysegul A.
    Yang, Wei
    Hortobagyi, Gabriel N.
    Buchholz, Thomas A.
    Mittendorf, Elizabeth A.
    ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (09) : 2407 - 2412